SEZI Senzime AB (publ)
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue's opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz Analyzer and OnZurf Probe. The company has a strategic connectivity and licensing agreement with Masimo that grants Senzime the rights to use some of Masimo's intellectual property; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About Senzime (STO: SEZI)
›
Senzime (STO: SEZI) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 59 employees.
The shares were at 3.295 SEK on 19 November 2026, down 38.9% over 52 weeks. Its 52-week range is 2.350 SEK to 6.000 SEK: the price is 45.1% below the high and 40.2% above the low.
Its market capitalisation is 518.02M SEK.
Senzime reports return on equity of -45.1%, an operating margin of -95.7% and revenue up 13.7% year over year.
It holds more cash than debt, a net cash position of 7.77M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 7.830 SEK is 137.6% above the current price. The next earnings report is expected on 28 January 2027.